HRAS and ovarian cancer: To determine the impact of INHBA(+) CAFs on ovarian cancer progression in vivo, we used two syngeneic ovarian cancer models: the FVB BR-luc (genotype p53−/−; Brca1−/−; Myc; Akt)36,37 and the peritoneal abrasion-facilitated C57BL/6 syngeneic SO model (genotype p53−/−; Myc; Hras)38.